EU-CTR 536/2014 – publishing clinical trial documents through CTIS
The European Union Clinical Trial Regulation (EU CTR) 536/2014 has increased transparency requirements for sponsors conducting clinical trials in the EU. Documents within clinical trial applications (CTA) need to be redacted for protection of personal data (PPD) and commercially confidential information (CCI), and plain language summaries for protocols (recommended) and results (required) need to be written.
Krystelis runs a quarterly closed forum with sponsor representatives who are involved with managing CTAs under EU CTR. This facilitates an open exchange of ideas on challenges and experiences with EU CTR.
Krystelis EU CTR Services
